New variant BA.2.86 has a genetic difference from prior strains on par with Omicron.
The strain's emergence comes as drugmakers have been preparing to roll out new COVID-19 vaccines next month aimed at the XBB strains of the virus, of which EG.5 is closely related. Moderna announced Thursday that its preliminary clinical trial data from the new shots confirmed "a significant boost in neutralizing antibodies" for EG.5.
Those could face a setback if BA.2.86 is able to spread more widely. Bloom said he thinks the strain's changes are enough to risk making the XBB-targeted vaccines a "fairly poor match" to BA.2.86.
But he underscored that BA.2.86 remains rare for now, and other defenses mounted by the body may also still work to fend off the highly-mutated variant.
Those could face a setback if BA.2.86 is able to spread more widely. Bloom said he thinks the strain's changes are enough to risk making the XBB-targeted vaccines a "fairly poor match" to BA.2.86.
But he underscored that BA.2.86 remains rare for now, and other defenses mounted by the body may also still work to fend off the highly-mutated variant.
Comment